Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

You may be eligible if

• Key Eligibility Criteria:
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Confirmed recurrent Stage IV NSCLC which progressed while on treatment with EGFR TKI
• Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
• Documented evidence of an EGFR mutation known to be associated with an EGFR TKI sensitivity
• No T790M mutation or small cell transformation including an assessment from tumor biopsy obtained while on or subsequent to the most recent EGFR TKI therapy
• Acceptable laboratory results as indicated by protocol
• Acceptable cardiac function as indicated by protocol
• Family history of long corrected QT interval (QTc) syndrome
• Symptomatic central nervous system (CNS) lesions
• Radiation therapy within 2 weeks prior to the first dose of study medication
• Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose of study medication
• Concurrent active malignancy requiring systemic treatment
• Any other serious uncontrolled medical disorders or psychological conditions that may interfere with study conduct including but not limited to: clinically significant active infection (e.g., tuberculosis, viral hepatitis, human immunodeficiency virus \[HIV\]), recent (within 6 months) myocardial infarction or unstable angina, congestive heart failure, poorly-controlled hypertension or diabetes, concurrent active malignancy, or psychiatric condition that may interfere with the patient's ability to follow study procedures
• Pregnant or breast-feeding